Drug intelligence / Profile preview

MVA-PEV

Development stage: Unknown
Lead developer: Nouscom
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MVA-PEV is a personalized cancer vaccine component developed by Nouscom. It utilizes a Modified Vaccinia Ankara (MVA) viral vector to deliver patient-specific neoantigens identified through next-generation sequencing (NGS) of tumor biopsies. In the NOUS-PEV clinical program, MVA-PEV is used as a booster following a prime with GAd-PEV (a Great Ape Adenoviral vector). This heterologous prime-boost strategy is designed to induce a robust and broad T-cell response against multiple tumor-specific mutations. It is currently being evaluated in combination with pembrolizumab for the treatment of advanced cutaneous melanoma and non-small cell lung cancer (NSCLC).

Other names: Modified Vaccinia Ankara-Personalized Vaccine

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on MVA-PEV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-PEV.

Explore the full profile